SCHEMBL2346144

SCHEMBL2346144

COC(Cc1ccccc1)(C(=O)O)C1=COCO1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.37
HIF1A Q16665 1/20 0.37
PPARG P37231 1/20 0.35
PPARA Q07869 1/20 0.35
TSHR P16473 2/20 0.33
PTPN2 P17706 1/20 0.33
PTPN1 P18031 1/20 0.33
PTPRA P18433 1/20 0.33
PTPRB P23467 1/20 0.33
ALDH1A1 P00352 3/20 0.32
RECQL P46063 1/20 0.32
MMP8 P22894 1/20 0.32
CYP3A4 P08684 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
KCNH2 Q12809 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5045640 0.78 SLC1A3 (0.39) PPARAMMP8RAB9AKMT2A
SCHEMBL4823560 0.73 CYP1A2 (0.48) SMN1; SMN2HIF1ATSHRMMP8CYP2C9
SCHEMBL3819421 0.72 CA12 (0.39) PPARGPPARAALDH1A1RECQLCA1
SCHEMBL8515125 0.71 SMN1; SMN2 (0.38) SMN1; SMN2HIF1ATSHRCYP2C9CYP2C19
SCHEMBL15262579 0.71 SMN1; SMN2 (0.38) SMN1; SMN2HIF1ATSHRCYP2C9CYP2C19
SCHEMBL1154824 0.71
SCHEMBL17825490 0.71 SMN1; SMN2 (0.43) SMN1; SMN2HIF1APPARGPPARATSHR
SCHEMBL16861319 0.70 PTPN1 (0.41) SMN1; SMN2HIF1APPARGPPARAPTPN2
SCHEMBL3443952 0.70 CYP2C9 (0.39) SMN1; SMN2HIF1AALDH1A1RECQLMMP8
SCHEMBL8874556 0.70 KIF11 (0.37) SMN1; SMN2HIF1ARECQLCYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2222645-B1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS HOFFMANN LA ROCHE (CH) 2013-03-20 EP disclosed
US-8008503-B2 Methyl-benzimidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2011-08-30 US disclosed
US-20100331371-A1 METHYL-BENZIMIDAZOLE DERIVATIVES BENSON GREGORY MARTIN 2010-12-30 US disclosed
US-7825258-B2 Methyl-benzimidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2010-11-02 US disclosed
US-20090131482-A1 METHYL-BENZIMIDAZOLE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2009-05-21 US disclosed
EP-1567498-B1 MANDELIC ACID DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-01-23 EP disclosed
US-7129238-B2 Mandelic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2006-10-31 US disclosed
EP-1567498-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-08-31 EP disclosed
US-20040122057-A1 Novel mandelic acid derivatives HOFFMANN-LA ROCHE INC. 2004-06-24 US disclosed
WO-2004048335-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122057-A1 Novel mandelic acid derivatives F7, F11, F9 SMN1; SMN2 3242/4885HIF1A 251/4885PPARG 4757/4885
US-20090131482-A1 METHYL-BENZIMIDAZOLE DERIVATIVES HDAC10, CYP3A4, ECI1 SMN1; SMN2 3391/4885HIF1A 2609/4885PPARG 184/4885
US-20100331371-A1 METHYL-BENZIMIDAZOLE DERIVATIVES HDAC10, CYP3A4, ECI1 SMN1; SMN2 3391/4885HIF1A 2609/4885PPARG 184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.